Studies on effectiveness and safety of vaccination with H5N1 prepandemic vaccines, and cross-immunity among H5N1 viruses - Tests on vaccination with H5N1 prepandemic vaccines

Fujita Health University0 个研究点目标入组 200 人开始时间: 2016年10月13日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) A person who clearly had a history of anaphylaxis to food or drugs. 2) A person who possibly have allergy to chicken eggs, chicken meet, and something derived from chicken. 3) A person who was diagnosed with immunodeficiency syndrome, or who has relatives with congenital immunodeficiency. 4) A person who has severe cardiovascular, hematological, respiratory, hepatic, renal, gastrointestinal, or psychoneuronal disorders. 5) A person who has previous history of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM). 6) A person with respiratory diseases including interstitial pneumonia or bronchial asthma. 7) A person who received investigational and experimental drugs for other clinical trials within 4 months of entry. 8) A person who received live attenuated vaccines within 27 days of entry or inactivated vaccines and toxoids within 6 days of entry. 9) A person who is pregnant, is suspected to be pregnant, or a woman with breast-feeding. 10) A woman who received intravenous immunoglobulin (IVIG) or blood transfusion within 3 months of entry or who received IVIG more than 200 mg/kg within 6 months of entry. 11) A person whom researchers and doctors in charge of this study judge unsuitable for this clinical trial.

发起方